Hers vs Willow: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

Willow beats Hers overall, scoring 8.2/10 vs 7.3/10. Hers is more affordable at $199/mo vs $299/mo. Choose Hers for women who want brand-name wegovy (injection or pill) at $149. Choose Willow for users who want comprehensive clinical support with flexibili.

A side-by-side comparison of Hers and Willow covering pricing, scores, medication types, insurance, and more to help you decide.

Hers

#35 of 48

7.3/10

The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership — alongside their existing compounded semaglutide and new compounded tirzepatide programs.

Visit Hers

Higher Rated

Willow

#8 of 48

8.2/10

Personalized GLP-1 weight loss with ongoing clinical support. Compounded semaglutide and tirzepatide only — Willow explicitly does not prescribe brand-name Wegovy or Zepbound. Added oral compounded semaglutide tablets as a non-injectable option.

Visit Willow

Feature	Hers	Willow
Our Score	7.3/10	8.2/10
Starting Price	$199/mo	$299/mo
Medication Type	Both	Compounded
Insurance Accepted	No	No
Best For	Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand	Users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes
Ranking	#35	#8

Pros & Cons Compared

Hers

Pros

+2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
+Zepbound access via the Lilly/Hims-Hers partnership announced 2026
+Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
+Broader women's health platform — integrates weight loss with hormonal, skin, and wellness services

Cons

−Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
−Generic support experience — large patient volume means less personalized attention
−Compounded pricing starts at $199/mo but stepped pricing applies at higher doses
−Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership — read as access, not value

Willow

Pros

+Includes monthly provider check-ins and dose adjustments at no extra cost
+Offers both injectable AND oral compounded semaglutide — one of few platforms with a daily oral tablet option
+$299/mo all-in for compounded semaglutide with monthly provider support
+90%+ patient retention rate after 3 months per their published outcomes data

Cons

−Compounded-only — no brand-name Wegovy or Zepbound through the platform
−Tirzepatide pricing reaches $499-$524 at higher doses — starting dose is $399/mo
−Cash-pay only — no insurance billing, though they provide superbills for FSA/HSA
−Founded in 2024 — less track record than Ro or Hims, though growth has been fast

Our Verdict

Willow edges out Hers with a score of 8.2/10 vs 7.3/10. If budget is your priority, Hers starts at $199/mo compared to Willow's $299/mo. Hers offers both brand-name and compounded medications, giving you more flexibility. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand. Choose Willow if you want: users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither Hers nor Willow feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review